- Season 1 Episode 1 (S1E1) on “Optimally Targeting TIGIT”
LEXINGTON, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will host its inaugural Agenus Insights on “Optimally Targeting TIGIT” on Thursday, February 11, 2021 at 1:00 p.m. ET.
This R&D miniseries, a brief yet concise summary of key insights into the most impactful areas of research in immuno-oncology and Agenus’ contributions to them, will include a 15-minute presentation and a 15-minute Q&A session.
S1E1, “Optimally Targeting TIGIT,” will be hosted by Dr. Steven O’Day, Chief Medical Officer, and Dr. Dhan Chand, Scientific Director, Head of Drug Discovery.
The webinar will begin with a fast-paced discussion by Dr. Steven O’Day and Dr. Dhan Chan highlighting the clinical validation of TIGIT as an anti-cancer target and the rationale for Agenus’ Fc-enhanced design. The remainder of the webinar will be made available for a Q&A session.
Registration for the webinar can be done in advance at https://agenusbio.zoom.us/webinar/register/WN_tOrL5VCkRoSh7lFKqOCKAA.
A replay will be available after the webinar on the Events & Presentations page of the Agenus website at https://investor.agenusbio.com/events-and-presentations.
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and Twitter.
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding TIGIT. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.